Recent Transactions

29-Nov-18
$86 million
United States flag
Target: 

Wave Computing

flag not available

Advised Wave Computing,  a leading artificial intelligence solutions company developing proprietary dataflow-based architecture systems, on its successful $86mm Series E financing

24-Oct-18
$41 million
United States flag
Target: 

TeePublic

Australia flag
Acquiror: 
Redbubble

Advised Redbubble, a global online independent artist community and marketplace, on the acquisition of TeePublic, a similar online platform, and associated A$61 million equity raising

15-Aug-18
$3.9 billion
Canada flag
Target: 

Common shares and common share purchase warrants in Canopy Growth

United States flag
Acquiror: 
Constellation Brands

Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants

25-Jul-18
$145 million
United States flag
Target: 

Park Electrochemical (Electronics Business)

Japan flag
Acquiror: 
AGC Inc.

Advised Park Electrochemical, a leading high-performance electronics materials manufacturer, on the sale of its Electronics Business to AGC Inc.

15-Jun-18
$NA
United States flag
Target: 

MIPS Tech

United States flag
Acquiror: 
Wave Computing

Advised Wave Computing, an artificial intelligence solutions company developing proprietary dataflow-based architecture systems, on the acquisition of MIPS Tech, a leading provider of processor architecture IP, and other strategic initiatives

02-May-18
$3.7 billion
Canada flag
Target: 

Concordia International Corp.

flag not available

Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt

27-Mar-18
$13.0 billion
Switzerland flag
Target: 

Novartis AG’s 36.5% stake in Consumer Health Joint Venture

United Kingdom flag
Acquiror: 
GlaxoSmithKline plc

Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture

18-Dec-17
$1.1 billion
United States flag
Target: 

Cayan, LLC

United States flag
Acquiror: 
Total System Services, Inc.

Advised Total System Services, a provider of payment processing, merchant services and related payment services, on acquiring Cayan, a payment technology company focused on integrated solutions and merchant acquiring

15-Dec-17
$6.0 billion
United States flag
Target: 

Avaya

flag not available

Advised The Bank of New York Mellon in its role as the Indenture Trustee to selected First Lien Notes throughout Avaya’s Chapter 11 proceedings

30-Nov-17
$NA
Germany flag
Target: 

MorphoSys AG

China flag
Acquiror: 
I-Mab

Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab

31-Oct-17
$2.0 billion
South Africa, Switzerland flags
Target: 

Hirslanden Private Hospital Group

flag not available

Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt

12-Jul-17
$227 million
United States flag
Target: 

Wells Fargo Share Registration & Service business

United Kingdom flag
Acquiror: 
Equiniti Group plc

Advised Equiniti Group plc, a UK based specialist technology outsourcer providing non-discretionary payment and administration services, on the acquisition of Wells Fargo's Shareowner Services business, and acted as joint sponsor to Equiniti's associated £122 million rights issue

03-Apr-17
$400 million
United States flag
Target: 

Cheetahmail

United States flag
Acquiror: 
Vector Capital

Advised Vector Capital on the acquisition of Cheetahmail from Experian plc

25-Jan-17
$325 million
United States flag
Target: 

Ad Hoc Group of Senior Secured Noteholders

flag not available

Advised the Ad Hoc Group of Senior Secured Noteholders in connection with the restructuring of Goodman Networks.

10-Jan-17
$204 million
United States flag
Target: 

Derma Sciences, Inc.

United States flag
Acquiror: 
Integra LifeSciences Holdings Corporation

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on its sale to Integra LifeSciences Holdings Corporation, a global leader in medical technology

09-Jan-17
$465 million
United States flag
Target: 

Palatin Technologies, Inc. lead product candidate, Rekynda

United States flag
Acquiror: 
AMAG Pharmaceuticals, Inc.

Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.

06-Dec-16
$1.8 billion
U.K., German flags
Target: 

Host Europe Group

United States flag
Acquiror: 
GoDaddy

Advised GoDaddy, the largest domain name registrar worldwide and a leading web hosting provider, on its acquisition of Host Europe Group, the largest privately owned web services provider in Europe

24-Nov-16
$NA
Israel flag
Target: 

Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.

Switzerland flag
Acquiror: 
Rivopharm SA

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA

23-Nov-16
$NA
Israel flag
Target: 

Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.

France flag
Acquiror: 
Arrow Generiques SAS

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).

13-Oct-16
$NA
U.S.A., Canada flags
Target: 

Concordia International Corp

flag not available

Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process

05-Oct-16
$775 million
U.K., Ireland flags
Target: 

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m) 

05-Oct-16
$NA
Israel flag
Target: 

Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).

04-Oct-16
$223 million
U.S.A., U.K. flags
Target: 

US rights to Toprol-XL (AstraZeneca)

Canada flag
Acquiror: 
Aralez Pharmaceuticals Inc.

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

28-Jul-16
$80 million
United States flag
Target: 

BioD, LLC

United States flag
Acquiror: 
Derma Sciences, Inc.

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.

28-Jun-16
$NA
Israel flag
Target: 

US rights to an authorized generic version of Adderall XR

United States flag
Acquiror: 
Prasco Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR

Pages

show all